Cargando…
Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415476/ https://www.ncbi.nlm.nih.gov/pubmed/25960596 http://dx.doi.org/10.1155/2015/614145 |
_version_ | 1782369083475361792 |
---|---|
author | Reinstadler, Sebastian Johannes Klug, Gert Feistritzer, Hans-Josef Metzler, Bernhard Mair, Johannes |
author_facet | Reinstadler, Sebastian Johannes Klug, Gert Feistritzer, Hans-Josef Metzler, Bernhard Mair, Johannes |
author_sort | Reinstadler, Sebastian Johannes |
collection | PubMed |
description | Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers. |
format | Online Article Text |
id | pubmed-4415476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44154762015-05-10 Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? Reinstadler, Sebastian Johannes Klug, Gert Feistritzer, Hans-Josef Metzler, Bernhard Mair, Johannes Dis Markers Review Article Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers. Hindawi Publishing Corporation 2015 2015-04-16 /pmc/articles/PMC4415476/ /pubmed/25960596 http://dx.doi.org/10.1155/2015/614145 Text en Copyright © 2015 Sebastian Johannes Reinstadler et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Reinstadler, Sebastian Johannes Klug, Gert Feistritzer, Hans-Josef Metzler, Bernhard Mair, Johannes Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title | Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title_full | Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title_fullStr | Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title_full_unstemmed | Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title_short | Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? |
title_sort | copeptin testing in acute myocardial infarction: ready for routine use? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415476/ https://www.ncbi.nlm.nih.gov/pubmed/25960596 http://dx.doi.org/10.1155/2015/614145 |
work_keys_str_mv | AT reinstadlersebastianjohannes copeptintestinginacutemyocardialinfarctionreadyforroutineuse AT kluggert copeptintestinginacutemyocardialinfarctionreadyforroutineuse AT feistritzerhansjosef copeptintestinginacutemyocardialinfarctionreadyforroutineuse AT metzlerbernhard copeptintestinginacutemyocardialinfarctionreadyforroutineuse AT mairjohannes copeptintestinginacutemyocardialinfarctionreadyforroutineuse |